以岭药业“盐酸美金刚”原料药上市获批

Group 1 - Yiling Pharmaceutical's subsidiary Hengshui Wanyang received approval from the National Medical Products Administration for the listing application of Memantine Hydrochloride, a drug used to treat moderate to severe Alzheimer's disease [1] - Memantine Hydrochloride is a non-competitive NMDA receptor antagonist that blocks pathological increases in glutamate concentration, preventing neuronal damage [1] - The Alzheimer's disease report of 2024 indicates approximately 16.9 million dementia patients in China, with a prevalence rate of about 1.19‰, which is rapidly increasing due to population aging [1] Group 2 - The anti-dementia market in China is valued at 1.56 billion yuan, with Memantine being a first-line treatment drug holding a market share of 22% [1] - The market capacity for Memantine Hydrochloride in China is expected to reach 340 million yuan by 2025, with a year-on-year growth of 11%, and sales volume projected to be 160 million tablets, reflecting a 19% increase [1] - Yiling Pharmaceutical aims to enhance its market share following the domestic approval of Memantine Hydrochloride, anticipating steady demand growth due to the aging population [1] Group 3 - Yiling Pharmaceutical also received approval for Anastrozole, a drug widely used for treating estrogen-related tumors, just days prior [2] - The company’s subsidiary Beijing Yiling Bio holds the formulation approval for Anastrozole tablets, which are expected to achieve integrated production of raw materials and formulations this year, enhancing market competitiveness [2] - Yiling Pharmaceutical plans to accelerate the international registration and overseas sales of Anastrozole raw materials, targeting markets in Europe and the United States [2]